Inmazeb

Active Ingredient(s): Atoltivimab + Odesivimab + Maftivimab
FDA Approved: * October 14, 2020
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Antiviral

Atoltivimab/maftivimab/odesivimab, developed as REGN-EB3 and sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus).[2] It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.[2] The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are al... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Inmazeb Intravenous Injection, Solution
NDC: 61755-018
Labeler:
Regeneron Pharmaceuticals, Inc.
Inmazeb Intravenous Injection, Solution
NDC: 61755-019
Labeler:
Regeneron Pharmaceuticals, Inc.